search icon
avxl-img

Anavex Life Sciences Corp, Common Stock

AVXL

NSQ

$9.945

-$0.16

(-1.58%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$868.39M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
950.49K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.80
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$4.93 L
$14.44 H
$9.945

About Anavex Life Sciences Corp, Common Stock

Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Its lead drug candidate, ANAVEX 2-73 (blarcamesine), which has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. The ANAVEX 2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The company's ANAVEX 3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a clinical stage drug candidate demonstrating disease-modifying activity against the Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameAVXLSectorS&P500
1-Week Return-10.24%2.92%1.21%
1-Month Return-8.51%1.03%3.67%
3-Month Return18.82%2.68%9.23%
6-Month Return14.31%-7.31%5.43%
1-Year Return57.61%-12.28%16.62%
3-Year Return-16.22%-0.25%50.34%
5-Year Return124.49%24.7%90.93%
10-Year Return78.87%75.94%207.03%

Financials

Sep '20Sep '21Sep '22Sep '23Sep '245YR TREND
Total Revenue-----[{"date":"2020-09-30","value":"-","profit":true},{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true},{"date":"2024-09-30","value":"-","profit":true}]
Cost of Revenue-----[{"date":"2020-09-30","value":"-","profit":true},{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true},{"date":"2024-09-30","value":"-","profit":true}]
Gross Profit-----[{"date":"2020-09-30","value":"-","profit":true},{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true},{"date":"2024-09-30","value":"-","profit":true}]
Gross Margin-----[{"date":"2020-09-30","value":"-","profit":true},{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true},{"date":"2024-09-30","value":"-","profit":true}]
Operating Expenses30.94M41.95M50.99M55.76M52.88M[{"date":"2020-09-30","value":55.49,"profit":true},{"date":"2021-09-30","value":75.23,"profit":true},{"date":"2022-09-30","value":91.44,"profit":true},{"date":"2023-09-30","value":100,"profit":true},{"date":"2024-09-30","value":94.84,"profit":true}]
Operating Income(30.76M)(41.92M)(50.99M)(47.50M)(52.88M)[{"date":"2020-09-30","value":-3075800000,"profit":false},{"date":"2021-09-30","value":-4192100000,"profit":false},{"date":"2022-09-30","value":-5098600000,"profit":false},{"date":"2023-09-30","value":-4749800000,"profit":false},{"date":"2024-09-30","value":-5287700000,"profit":false}]
Total Non-Operating Income/Expense5.01M4.31M4.31M8.23M17.20M[{"date":"2020-09-30","value":29.14,"profit":true},{"date":"2021-09-30","value":25.05,"profit":true},{"date":"2022-09-30","value":25.08,"profit":true},{"date":"2023-09-30","value":47.88,"profit":true},{"date":"2024-09-30","value":100,"profit":true}]
Pre-Tax Income(26.26M)(37.64M)(47.62M)(47.50M)(43.00M)[{"date":"2020-09-30","value":-2625800000,"profit":false},{"date":"2021-09-30","value":-3764100000,"profit":false},{"date":"2022-09-30","value":-4762000000,"profit":false},{"date":"2023-09-30","value":-4749800000,"profit":false},{"date":"2024-09-30","value":-4300200000,"profit":false}]
Income Taxes22.66K267.56K358.49K(7.00K)(2.29M)[{"date":"2020-09-30","value":6.32,"profit":true},{"date":"2021-09-30","value":74.64,"profit":true},{"date":"2022-09-30","value":100,"profit":true},{"date":"2023-09-30","value":-1.95,"profit":false},{"date":"2024-09-30","value":-639.07,"profit":false}]
Income After Taxes(26.28M)(37.91M)(47.98M)(47.49M)(40.71M)[{"date":"2020-09-30","value":-2628066400,"profit":false},{"date":"2021-09-30","value":-3790856500,"profit":false},{"date":"2022-09-30","value":-4797849200,"profit":false},{"date":"2023-09-30","value":-4749100000,"profit":false},{"date":"2024-09-30","value":-4071100000,"profit":false}]
Income From Continuous Operations(26.28M)(37.91M)(47.98M)(47.51M)(43.00M)[{"date":"2020-09-30","value":-2628047000,"profit":false},{"date":"2021-09-30","value":-3790863400,"profit":false},{"date":"2022-09-30","value":-4797791900,"profit":false},{"date":"2023-09-30","value":-4750500000,"profit":false},{"date":"2024-09-30","value":-4300200000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-09-30","value":"-","profit":true},{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true},{"date":"2024-09-30","value":"-","profit":true}]
Net Income(26.28M)(37.91M)(47.98M)(47.49M)(43.00M)[{"date":"2020-09-30","value":-2628000000,"profit":false},{"date":"2021-09-30","value":-3790900000,"profit":false},{"date":"2022-09-30","value":-4797800000,"profit":false},{"date":"2023-09-30","value":-4749100000,"profit":false},{"date":"2024-09-30","value":-4300200000,"profit":false}]
EPS (Diluted)(0.45)(0.53)(0.62)(0.60)(0.52)[{"date":"2020-09-30","value":-45,"profit":false},{"date":"2021-09-30","value":-53,"profit":false},{"date":"2022-09-30","value":-62,"profit":false},{"date":"2023-09-30","value":-60,"profit":false},{"date":"2024-09-30","value":-52,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

AVXL
Cash Ratio 13.41
Current Ratio 13.41

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

AVXL
ROA (LTM) -27.41%
ROE (LTM) -43.64%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

AVXL
Debt Ratio Lower is generally better. Negative is bad. 0.11
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.89

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

AVXL
Trailing PE NM
Forward PE 4.20
P/S (TTM) 0.00
P/B 9.39
Price/FCF NM
EV/R 0.00
EV/Ebitda NM
PEG NM

FAQs

What is Anavex Life Sciences Corp share price today?

Anavex Life Sciences Corp (AVXL) share price today is $9.945

Can Indians buy Anavex Life Sciences Corp shares?

Yes, Indians can buy shares of Anavex Life Sciences Corp (AVXL) on Vested. To buy Anavex Life Sciences Corp from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in AVXL stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Anavex Life Sciences Corp be purchased?

Yes, you can purchase fractional shares of Anavex Life Sciences Corp (AVXL) via the Vested app. You can start investing in Anavex Life Sciences Corp (AVXL) with a minimum investment of $1.

How to invest in Anavex Life Sciences Corp shares from India?

You can invest in shares of Anavex Life Sciences Corp (AVXL) via Vested in three simple steps:

  • Click on Sign Up or Invest in AVXL stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Anavex Life Sciences Corp shares
What is Anavex Life Sciences Corp 52-week high and low stock price?

The 52-week high price of Anavex Life Sciences Corp (AVXL) is $14.44. The 52-week low price of Anavex Life Sciences Corp (AVXL) is $4.93.

What is Anavex Life Sciences Corp price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Anavex Life Sciences Corp (AVXL) is 9.39

What is the Market Cap of Anavex Life Sciences Corp?

The market capitalization of Anavex Life Sciences Corp (AVXL) is $868.39M

What is Anavex Life Sciences Corp’s stock symbol?

The stock symbol (or ticker) of Anavex Life Sciences Corp is AVXL

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top